Cyanine-loaded lipid nanoparticles for improved in vivo fluorescence imaging

Texier, Isabelle; Goutayer, Mathieu; Silva, Anabela Da; Guyon, Laurent; Djaker, Nadia; Josserand, Véronique; Neumann, Emmanuelle; Bibette, Jérôme; Vinet, F.

doi:10.1117/1.3213606

Cited by 139 publications

(147 citation statements)

References 46 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…For this purpose, DiD was encapsulated in LNCs because the fluorescence and physico-chemical properties of DiD supported the choice of this fluorescence labeling. It is highly fluorescent in lipophilic nanocarriers and weakly fluorescent in aqueous media (19); the auto-fluorescence wavelength emitted by animals is limited because it is a near-infrared fluorophore (20,21), and there is a strong fluorescence labeling stability of the nanocarrier (no DiD release even in favorable media) (16).…”

Section: Discussionmentioning

confidence: 99%

Passive and specific targeting of lymph nodes: the influence of the administration route

Pitorre¹,

Bastiat²,

Chatel³

et al. 2015

European Journal of Nanomedicine

View full text Add to dashboard Cite

Abstract:Patients diagnosed with an advanced-stage cancer present a dismal prognosis due to the presence of metastases. From the primary tumor, the cancer cells are disseminated via lymphatic circulation; metastases develop initially in lymph nodes. Therefore, the targeting of lymph nodes needs to be improved in the design of future chemotherapy, and one way to ensure this targeting is by using the subcutaneous (SC) route. Using lipid nanocapsules (LNCs) (40 nm and fluorescently-labeled with DiD) as nanocarriers, a correlation between the SC injection site (behind the neck, the right and left flanks, and above the tail) for LNC administration and specific lymph node accumulation (left and right cervical, axillary and inguinal lymph nodes) was achieved for SpragueDawley rats. The pharmacokinetic and biodistribution profiles confirmed the absence of LNCs in systemic circulation after SC administration due to the optimal size of the LNCs. With appropriate SC administration, LNCs can accumulate in specific lymph nodes, whereas IV administration led to a weak accumulation of LNCs in all lymph nodes. Specific accumulation followed the lymph flow: bottom-up from the lower to upper limbs and top down from the head, with two lymph circulation partitions: right upper limb and the rest. Administration above the tail presented high inguinal and axillary lymph node accumulation whereas weak accumulation was observed after administration behind the neck. LNCs administered in the left flank only accumulated in the left inguinal and axillary lymph nodes, whereas left and right inguinal and axillary lymph nodes presented accumulation after administration in the right flank. Cervical lymph nodes, in the opposite direction of lymph flow, were never targeted after SC administration, whatever the injection site.

show abstract

Section: Discussionmentioning

confidence: 99%

Passive and specific targeting of lymph nodes: the influence of the administration route

Pitorre¹,

Bastiat²,

Chatel³

et al. 2015

European Journal of Nanomedicine

View full text Add to dashboard Cite

show abstract

“…Liposomes are highly biocompatible nanocarriers comprised of extremely cheap raw materials (soybean oil, lecithin etc.) that permit the use of the simplest fabrication methods (Texier et al, 2009). Doxil ® (DOX-containing PEGylated liposome) was the first therapeutic liposomal delivery vehicle approved by the FDA in 1995 (Jain and Stylianopoulos, 2010).…”

Section: Drug Deliverymentioning

confidence: 99%

Nanomedicine and epigenome. Possible health risks

Smolkova

Dušinská

Gábelová

2017

Food and Chemical Toxicology

View full text Add to dashboard Cite

a b s t r a c tNanomedicine is an emerging field that combines knowledge of nanotechnology and material science with pharmaceutical and biomedical sciences, aiming to develop nanodrugs with increased efficacy and safety. Compared to conventional therapeutics, nanodrugs manifest higher stability and circulation time, reduced toxicity and improved targeted delivery. Despite the obvious benefit, the accumulation of imaging agents and nanocarriers in the body following their therapeutic or diagnostic application generates concerns about their safety for human health. Numerous toxicology studies have demonstrated that exposure to nanomaterials (NMs) might pose serious risks to humans. Epigenetic modifications, representing a non-genotoxic mechanism of toxicant-induced health effects, are becoming recognized as playing a potential causative role in the aetiology of many diseases including cancer. This review i) provides an overview of recent advances in medical applications of NMs and ii) summarizes current evidence on their possible epigenetic toxicity. To discern potential health risks of NMs, since current data are mostly based upon in vitro and animal models, a better understanding of functional relationships between NM exposure, epigenetic deregulation and phenotype is required.

show abstract

“…The DiR was used as a fluorescent probe 23 and was loaded into the T-CS micelles for in vivo fluorescent imaging investigation. The xenografted tumor models were established by subcutaneous injection of SKOV3 cells (5×10 6 cells in 100 μL of serum-free Dulbecco's Modified Eagle's Medium) into the left flank and A549 cells (5×10 6 cells in 100 μL of serum-free Dulbecco's Modified Eagle's Medium) into the right flank of male BALB/C+nu/F1 nude mice.…”

Section: In Vitro Cellular Competitive Uptake Of Dox-loaded Micellesmentioning

confidence: 99%

TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting

Chen¹,

Yan²,

Yi³

et al. 2014

IJN

View full text Add to dashboard Cite

Nowadays, a real challenge in cancer therapy is to design drug delivery systems that can achieve high concentrations of drugs at the target site for improved therapeutic effect with reduced side effects. In this research, we designed and synthesized a homing peptide-(TNYLFSPNGPIA, TNYL) modified chitosan-g-stearate (CS) polymer micelle (named T-CS) for targeting delivery. The peptide displayed specific binding affinity to EphB4 which is a member of the Eph family of receptor tyrosine protein kinases. The amphiphilic polymer T-CS can gather into micelles by themselves in an aqueous environment with a low critical micelle concentration value (91.2 μg/L) and nano-scaled size (82.1±2.8 nm). The drug encapsulation efficiency reached 86.43% after loading the hydrophobic drug doxorubicin (DOX). The cytotoxicity of T-CS/DOX against SKOV3 cells was enhanced by approximately 2.3-fold when compared with CS/DOX. The quantitative and qualitative analysis for cellular uptake indicated that TNYL modification can markedly increase cellular internalization in the EphB4-overexpressing SKOV3 cell line, especially with a short incubation time. It is interesting that relatively higher uptake of the T-CS/DOX micelles by SKOV3 cells (positive-EphB4) than A549 cells (negative-EphB4) was observed when the two cells were co-incubated. Furthermore, in vivo distribution experiment using a bilateral-tumor model showed that there was more fluorescence accumulation in the SKOV3 tumor than in the A549 tumor over the whole experiment. These results suggest that TNYL-modified CS micelles may be promising drug carriers as targeting therapy for the EphB4-overexpressing tumor.

show abstract

Cyanine-loaded lipid nanoparticles for improved in vivo fluorescence imaging

Cited by 139 publications

References 46 publications

Passive and specific targeting of lymph nodes: the influence of the administration route

Passive and specific targeting of lymph nodes: the influence of the administration route

Nanomedicine and epigenome. Possible health risks

TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting

Contact Info

Product

Resources

About